LA
ARQT icon

LVW Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

LVW Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,091
Closed -$544K – 465
2026
Q1 		$544K Buy
23,091
+902
+4% +$23K 0.05% 199
2025
Q4 		$644K Buy
22,189
+1,535
+7% +$39.3K 0.07% 150
2025
Q3 		$389K Buy
20,654
+3,093
+18% +$48.8K 0.04% 232
2025
Q2 		$246K Buy
17,561
+3,095
+21% +$43.4K 0.03% 292
2025
Q1 		$226K Buy
14,466
+2,530
+21% +$35.6K 0.03% 283
2024
Q4 		$166K Buy
+11,936
New +$131K 0.02% 307

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

LVW Advisors's ARQT Position: Q2 2026 in Review

LVW Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 23,091 shares — an estimated $544K sold.

LVW Advisors first reported a position in ARQT in Q4 2024 and held it in 6 quarters. The position peaked at $644K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • LVW Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • LVW Advisors sold 23,091 Arcutis Biotherapeutics shares in Q2 2026, an estimated $544K.
  • LVW Advisors first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 6 quarters.
  • LVW Advisors's Arcutis Biotherapeutics position peaked at $644K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.